GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (XSWX:BION) » Definitions » Net Income Including Noncontrolling Interests

BB Biotech AG (XSWX:BION) Net Income Including Noncontrolling Interests : CHF-206.61 Mil (TTM As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is BB Biotech AG Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

BB Biotech AG's Net Income Including Noncontrolling Interests for the three months ended in Dec. 2023 was CHF109.12 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-206.61 Mil.

BB Biotech AG Net Income Including Noncontrolling Interests Historical Data

The historical data trend for BB Biotech AG's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Net Income Including Noncontrolling Interests Chart

BB Biotech AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 677.43 691.17 -404.81 -357.81 -206.61

BB Biotech AG Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.16 -253.86 -13.48 -48.39 109.12

BB Biotech AG Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-206.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BB Biotech AG Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

BB Biotech AG (XSWX:BION) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (XSWX:BION) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
LSE:GNS LSE:ONT LSE:PRTC LSE:BVXP LSE:OXB LSE:HVO LSE:AVCT LSE:4BB LSE:FUM LSE:FARN OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
BIONz:UK BBZA:Germany
Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
Website
https://www.bbbiotech.com
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.
Executives
Prof. Dr. Mads Krogsgaard Thomsen Supervisory Board

BB Biotech AG (XSWX:BION) Headlines

No Headlines